HDFC Pharma and Healthcare Fund · Direct · Growth
HDFC Mutual Fund · Managed by Nikhil Mathur
NAV
₹23.4590
as of 16 Nov 2026
Expense Ratio
1.01%
Lumpsum returns (CAGR)
- 1Y
- +30.32%
- 3Y
- +30.54%
- 5Y
- —
- Since Inception
- +31.45%
SIP returns (XIRR)
- 1Y
- +40.78%
- 3Y
- +27.31%
- 5Y
- —
- Since Inception
- +27.58%
Performance Comparison
Sectoral allocation
as of 31 Oct 2026- Pharmaceuticals & Biotechnology70.88%
- Healthcare Services24.84%
- Healthcare Equipment & Supplies2.18%
- Retailing0.89%
Each sector links to the mutual funds most exposed to it.
Thinking about HDFC Pharma and Healthcare Fund · Direct · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Compare with Similar Funds
Fund Details
Available transactions
Portfolio holdings
portfolio shared with HDFC Pharma and Healthcare Fund - Growth Option
- 1Divis Laboratories Ltd.9.44%
- 2Sun Pharmaceutical Industries Ltd.7.74%
- 3Dr Reddys Laboratories Ltd.6.66%
- 4Apollo Hospitals Enterprise Ltd.5.19%
- 5Alkem Laboratories Ltd.4.75%
- 6Cipla Ltd.4.06%
- 7Acutaas Chemicals Limited3.70%
- 8Max Healthcare Institute Limited3.44%
- 9Aster Dm Quality Care Limited3.37%
- 10Lupin Ltd.3.35%
What this fund does
HDFC Pharma and Healthcare Fund · Direct · Growth invests in stocks from a specific sector or theme, offering concentrated exposure to a particular area of the economy. These funds carry sector-specific risks but can deliver significant returns when the underlying sector performs well.
About This Fund
HDFC Pharma and Healthcare Fund · Direct · Growth is a Sectoral / Thematic mutual fund offered by HDFC Mutual Fund. The fund has been operational for over 3 years. The fund is managed by Nikhil Mathur. It benchmarks its performance against BSE Healthcare Index TRI. The current expense ratio is 1.01%.